Today's top story

EMA to consult on biosimilars regulatory requirements in 2025

The European Medicines Agency (EMA) could table proposals next year to relax requirements around the need for comparative efficacy trials in the development of biosimilar medicines, Out-Law has learned.

Life Sciences & Health

Legal Updates

Oft gelesen

We are working towards submitting your application. Thank you for your patience. An unknown error occurred, please input and try again.